MREO - Mereo BioPharma: Underfollowed British Company In Cancer And Rare Diseases
- MREO came to some prominence after Ultragenyx gave it a nice deal in December 2020.
- Its lead asset etigilimab has some early interesting data.
- It will take a few more years for the company to garner more investor interest.
For further details see:
Mereo BioPharma: Underfollowed British Company In Cancer And Rare Diseases